Victory Capital Management’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$128K Buy
11,721
+159
+1% +$1.99K ﹤0.01% 2250
2025
Q4
$149K Buy
11,562
+115
+1% +$1.48K ﹤0.01% 2237
2025
Q3
$148K Sell
11,447
-360
-3% -$4.81K ﹤0.01% 2253
2025
Q2
$210K Sell
11,807
-118
-1% -$2.06K ﹤0.01% 2239
2025
Q1
$213K Sell
11,925
-117
-1% -$2.66K ﹤0.01% 2208
2024
Q4
$359K Sell
12,042
-323
-3% -$6.84K ﹤0.01% 2110
2024
Q3
$193K Sell
12,365
-148
-1% -$2.68K ﹤0.01% 2233
2024
Q2
$214K Sell
12,513
-164
-1% -$2.88K ﹤0.01% 2186
2024
Q1
$198K Sell
12,677
-352
-3% -$5.18K ﹤0.01% 2224
2023
Q4
$195K Buy
+13,029
New +$174K ﹤0.01% 2240
2021
Q4
Sell
-2,420
Closed -$281K 2828
2021
Q3
$281K Sell
2,420
-429,934
-99% -$65M ﹤0.01% 2404
2021
Q2
$95.9M Sell
432,354
-101,708
-19% -$19.8M 0.09% 292
2021
Q1
$70.6M Buy
534,062
+83,276
+18% +$13.2M 0.07% 397
2020
Q4
$78M Buy
450,786
+409,159
+983% +$56M 0.09% 351
2020
Q3
$4.63M Buy
41,627
+8,910
+27% +$712K 0.01% 1213
2020
Q2
$1.94M Sell
32,717
-36,069
-52% -$2.37M ﹤0.01% 1438
2020
Q1
$4.63M Buy
68,786
+4,184
+6% +$331K ﹤0.01% 1292
2019
Q4
$5.44M Buy
64,602
+30,379
+89% +$2.45M 0.01% 1162
2019
Q3
$2.56M Buy
+34,223
New +$2.74M ﹤0.01% 1364

Other funds holding NVCR

Victory Capital Management's NVCR Position: Q1 2026 in Review

Victory Capital Management increased its NovoCure (NVCR) stake by 1.4% in Q1 2026, buying an estimated $1.99K and bringing the position to 11,721 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Victory Capital Management first reported a position in NVCR in Q3 2019 and has held it in 19 quarters since. The position peaked at $95.9M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Victory Capital Management held 11,721 shares of NovoCure worth $128K as of Q1 2026.
  • Victory Capital Management bought 159 NovoCure shares in Q1 2026, an estimated $1.99K.
  • NovoCure made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2250 holding.
  • Victory Capital Management first reported a position in NovoCure in Q3 2019 and has held it in 19 quarters since.
  • Victory Capital Management's NovoCure position peaked at $95.9M in Q2 2021.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.